$FHTX News

Foghorn: Downgrade 'Sell' Eli Lilly Exit FHD-909 And Shift To Preclinical Assets

Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2

TD Cowen Downgrades Foghorn Therapeutics to Hold

Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5

HC Wainwright & Co. Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5

BTIG Downgrades Foghorn Therapeutics to Neutral

Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Foghorn Therapeutics Halts FHD-909 Development After Phase 1 Clinical Data Review

FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug?

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

Foghorn Therapeutic Announces That The Company And Lilly Will Not Advance The FHD-909 Program Into The Clinical Development Expansion Phase

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $16.072M Beat $5.995M Estimate

Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?

Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript